anti-cd3-muc1 bispecific antibody
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2017 (NCT03146637)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1INHIBITOR
MUC1 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-cd3-muc1 bispecific antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03554395 | Phase 2 | Apr 5, 2018 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Guangzhou University, Jinan University |
| NCT03146637 | Phase 2 | May 1, 2017 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., People's Liberation Army of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. | For profit | 2 | 1 | 1 | 2017 |
| Guangzhou University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Jinan University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1